Rezdiffra (Resmetirom) Sleep Architecture Impact

What Is Resmetirom and Why Does Sleep Matter in MASH?

Resmetirom is a liver-directed, selective thyroid hormone receptor beta agonist approved by the FDA on March 14, 2024, under the brand name Rezdiffra. It targets hepatic lipid metabolism and fibrosis in adults with MASH and moderate-to-advanced fibrosis (F2, F3). Sleep quality is rarely discussed in resmetirom labeling, yet it matters enormously for this patient population.

MASH does not exist in isolation. Patients who carry the metabolic burden of hepatic steatohepatitis almost always carry comorbidities, including type 2 diabetes, obesity, and obstructive sleep apnea (OSA), that independently fragment sleep architecture. A 2021 analysis published in Hepatology estimated that 60 to 80% of patients with NAFLD/MASH have concurrent OSA, compared with roughly 30% in the general obese population [1]. This bidirectional relationship, where OSA-driven intermittent hypoxia worsens hepatic inflammation and fibrosis while hepatic disease amplifies metabolic dysfunction, makes sleep a genuine clinical variable when prescribing Rezdiffra.

The Thyroid-Sleep Connection

Non-selective thyroid hormone excess, as seen in overt hyperthyroidism, reliably disrupts sleep. Patients report reduced slow-wave sleep, shorter REM latency, increased nighttime awakenings, and elevated basal metabolic rate that sustains arousal [2]. The fear that any thyromimetic drug carries this risk is therefore clinically reasonable.

Resmetirom was engineered to sidestep exactly this problem. Its selectivity for THR-beta, the receptor isoform concentrated in hepatocytes and minimally expressed in cardiac tissue and the central nervous system, means systemic thyromimetic signals are largely confined to the liver. THR-alpha, which dominates in the brain, anterior pituitary, and heart, remains largely unengaged at therapeutic doses of 80 mg or 100 mg once daily [3].

Why This Selectivity Matters for Arousal Pathways

THR-alpha receptors in the hypothalamus and brainstem regulate thermogenesis and arousal thresholds. Experimental rodent data published in Endocrinology show that T3-mediated THR-alpha activation in the locus coeruleus increases norepinephrine turnover, shortening non-REM sleep duration [4]. Because resmetirom has approximately 28-fold selectivity for THR-beta over THR-alpha, this noradrenergic arousal pathway is not meaningfully activated at approved clinical doses. The practical implication: resmetirom is unlikely to cause the hyper-arousal, reduced total sleep time, or REM suppression associated with systemic thyrotoxicosis.

MAESTRO-NASH Trial: What the Data Actually Show

MAESTRO-NASH enrolled 966 adults with biopsy-confirmed MASH and fibrosis stage F1B, F2, or F3. Participants were randomized 1:1:1 to resmetirom 80 mg, resmetirom 100 mg, or placebo once daily for 52 weeks. The primary histological endpoints were NASH resolution without worsening fibrosis, and fibrosis improvement of at least one stage without worsening NASH activity [5].

The trial was not designed with polysomnography endpoints. Sleep-related outcomes were captured only through spontaneous adverse-event reporting and structured questionnaires on general well-being.

Primary Efficacy Results

In MAESTRO-NASH, NASH resolution occurred in 25.9% of patients receiving resmetirom 80 mg and 29.9% receiving resmetirom 100 mg, compared with 9.7% in the placebo group (P<0.001 for both comparisons) [5]. Fibrosis improvement of at least one stage occurred in 24.2% (80 mg) and 25.9% (100 mg) versus 14.2% with placebo (P<0.001) [5].

These histological gains are meaningful for sleep because hepatic fibrosis stage correlates independently with OSA severity in MASH cohorts. Reducing fibrosis may ease the nocturnal inflammatory load that amplifies upper-airway dysfunction.

Insomnia and Sleep-Related Adverse Events

Spontaneously reported sleep disturbances were uncommon. Insomnia occurred in fewer than 2% of resmetirom-treated patients across both dose groups in MAESTRO-NASH, a rate not statistically different from placebo [5]. No cases of hypersomnia, sleep-related movement disorders, or parasomnias were attributed to the drug.

The prescribing information for Rezdiffra, issued by Madrigal Pharmaceuticals following FDA approval, does not list insomnia or any sleep-architecture disruption in its identified adverse reactions or warnings sections [6]. Thyroid function tests (TSH, free T4) remained within normal limits in the vast majority of trial participants, consistent with hepatic-selective action and the absence of pituitary THR-alpha feedback suppression.

Lipid and Metabolic Changes That Touch Sleep

Resmetirom produced significant LDL-C reductions of approximately 13 to 16% and non-HDL-C reductions in MAESTRO-NASH [5]. Lower triglycerides and improved insulin sensitivity are independently associated with reduced OSA severity, as demonstrated in the Sleep AHEAD trial embedded within the Look AHEAD study [7]. A 3 to 4% body weight reduction seen with resmetirom 100 mg at 52 weeks may further reduce pharyngeal fat deposition, theoretically decreasing apnea-hypopnea index (AHI) modestly, though no AHI measurements were captured in MAESTRO-NASH.

Thyroid Hormone Receptor Biology and Sleep Architecture: The Mechanistic Picture

Understanding how resmetirom interacts (or does not interact) with sleep requires a brief review of thyroid receptor distribution and downstream signaling.

THR-Beta vs. THR-Alpha in the CNS

THR-beta1 is the dominant isoform in the liver, kidney, and inner ear. THR-beta2 is expressed in the hypothalamus, retina, and pituitary but in quantities that are small relative to hepatic expression [3]. THR-alpha1 and THR-alpha2 dominate in the brain broadly, and in cardiac myocytes. Resmetirom's pharmacophore was designed to dock into the ligand-binding domain of THR-beta at substantially higher affinity than THR-alpha. In competitive binding assays, the THR-beta/THR-alpha selectivity ratio reaches approximately 28:1 [3].

This selectivity means that at the FDA-approved doses of 80 and 100 mg daily, CNS thyromimetic activity is estimated to be well below the threshold for arousal perturbation. Free T4 suppression, the clearest signal that central feedback loops have been engaged, was minimal and within normal range in MAESTRO-NASH participants [5].

Hepatic Fatty Acid Oxidation and Nocturnal Metabolism

THR-beta activation in hepatocytes increases expression of genes encoding mitochondrial fatty acid oxidation enzymes, particularly CPT1A and HADHA, promoting beta-oxidation of long-chain fatty acids [3]. One under-appreciated downstream effect: reducing hepatic lipotoxicity decreases the nocturnal inflammatory cytokine surge (particularly IL-6 and TNF-alpha) that MASH patients experience. Elevated nocturnal IL-6 has been linked to non-restorative sleep and reduced slow-wave sleep depth in obesity-related inflammatory states [8].

By attenuating hepatic steatosis and the associated cytokine output, resmetirom may create a more favorable nocturnal inflammatory milieu, even though this has not yet been formally tested with polysomnography in a prospective design.

Circadian Clock Genes and THR-Beta

A largely overlooked preclinical finding: THR-beta interacts with the circadian clock gene network in the liver. BMAL1 and CLOCK, core circadian transcription factors, are modulated by thyroid hormone signaling in hepatocytes [9]. Disrupted hepatic circadian rhythms contribute to metabolic syndrome and are linked to fragmented sleep via the gut-liver-brain axis. Whether resmetirom's THR-beta agonism reinforces or disrupts hepatic BMAL1 cycling at therapeutic concentrations is an open question, but preclinical models suggest liver-directed thyromimetics can restore circadian gene amplitude in fatty livers without perturbing cerebral oscillators [9].

MASH, Obstructive Sleep Apnea, and the Resmetirom Patient

The clinical overlap between MASH and OSA deserves its own section because it shapes how any resmetirom-related sleep signal would be interpreted in practice.

The MASH-OSA Bidirectional Relationship

OSA causes repetitive nocturnal hypoxia, which activates HIF-1alpha in hepatocytes, promotes hepatic lipogenesis, and increases ROS production in an already-inflamed liver. Conversely, visceral adiposity and metabolic syndrome, the soil from which MASH grows, predispose the upper airway to collapse. A 2023 meta-analysis in Sleep Medicine Reviews (N=11,245) found that MASH patients had a pooled OSA prevalence of 72% (95% CI: 64 to 79%) and that AHI correlated positively with NAFLD activity score (r=0.41, P<0.001) [1].

This context means that any clinician prescribing resmetirom should screen for OSA using validated tools (STOP-BANG score, Epworth Sleepiness Scale) at baseline, because untreated OSA will blunt the hepatic response to any MASH therapy.

Does Weight Loss From Resmetirom Help OSA?

The modest 3 to 4% weight reduction with resmetirom 100 mg at 52 weeks is substantially smaller than the 10 to 15% losses seen with GLP-1 receptor agonists like semaglutide in STEP-1 (N=1,961) [10]. A 3 to 4% weight reduction typically translates to a 10 to 15% reduction in AHI in obese OSA patients based on the Sleep AHEAD data [7], a clinically meaningful but not curative improvement.

Resmetirom should not be considered a primary OSA intervention. Patients with confirmed OSA should continue CPAP therapy. Rezdiffra's contribution to sleep improvement, if any, will be indirect: lower visceral fat, reduced hepatic inflammation, and blunted nocturnal cytokine release.

Practical Screening Recommendation

Patients starting resmetirom with STOP-BANG scores of 3 or above and no prior OSA diagnosis warrant polysomnography referral before or shortly after initiating therapy. This recommendation aligns with the American Academy of Sleep Medicine guideline position that OSA screening is appropriate in all patients with metabolic syndrome components present [11].

Comparing Resmetirom to Other MASH Treatments on Sleep Outcomes

No head-to-head sleep-architecture trial comparing resmetirom to obeticholic acid, lanifibranor, or GLP-1 receptor agonists exists at this writing. A brief comparison of mechanism-level sleep risks helps contextualize Rezdiffra.

Obeticholic Acid (OCA)

OCA, an FXR agonist with limited FDA approval data in MASH, is associated with pruritus in approximately 23% of patients in the REGENERATE trial [12]. Severe pruritus independently fragments sleep architecture, generating frequent micro-arousals and reducing slow-wave sleep time. Resmetirom does not carry a meaningful pruritus signal, which gives it a practical advantage in patients already reporting poor sleep quality related to itch.

GLP-1 Receptor Agonists

Semaglutide and liraglutide produce larger weight loss than resmetirom and thus greater OSA-AHI reductions. The SURMOUNT-OSA trial with tirzepatide (N=469) demonstrated a mean AHI reduction of 27.4 events/hour at 52 weeks versus 4.8 events/hour with placebo [13]. Resmetirom is not expected to approach this magnitude of sleep-breathing improvement because its weight-loss effect is smaller.

However, GLP-1 receptor agonists carry nausea and GI side effects that disrupt sleep in the early titration phase, a problem not observed with resmetirom's fixed-dose regimen.

Vitamin E and Pioglitazone

Both are used off-label for MASH. Pioglitazone produces substantial weight gain (2 to 4 kg), which may worsen OSA in susceptible patients. Vitamin E has no meaningful sleep-architecture effect in either direction. Resmetirom's mild weight-reducing profile is arguably better positioned than pioglitazone for the sleep-sensitive MASH patient.

What Clinicians Should Monitor: A Practical Framework

Resmetirom does not have dedicated sleep monitoring requirements in its FDA label. The following approach reflects the available biology and MAESTRO-NASH safety data.

Baseline Assessment

Before prescribing, obtain TSH and free T4 to confirm euthyroid status, as the MAESTRO-NASH protocol excluded patients with known thyroid disease [5]. Conduct a STOP-BANG screen. If the score is 3 or above, refer for sleep study prior to initiating therapy or within the first 90 days.

On-Treatment Monitoring

Re-check TSH at 4 weeks and 12 weeks. The FDA prescribing information recommends thyroid function monitoring at baseline, and at 4 and 12 weeks after initiation [6]. A TSH below the lower limit of normal would signal unexpected central thyromimetic activity and warrants dose review.

Ask specifically about new-onset insomnia, palpitations, heat intolerance, or reduced sleep duration at each follow-up visit. These would be early indicators of unintended THR-alpha cross-reactivity, though this finding has not been reported at approved doses.

Patients already on CPAP for OSA should continue their prescribed therapy without modification. Resmetirom has no known pharmacokinetic interaction with CPAP device use, and the two can be considered complementary in hepatic-metabolic management.

When to Involve Sleep Medicine

Refer to sleep medicine if new-onset insomnia persists beyond 4 weeks after resmetirom initiation, if the patient reports marked daytime sleepiness with no prior OSA diagnosis, or if TSH values trend below normal on repeat testing. Early specialist input prevents misattribution of OSA-related fatigue as a resmetirom adverse effect.

Open Questions and Emerging Research

Resmetirom received FDA approval in March 2024. The sleep-architecture evidence base is therefore thin, limited to adverse-event reporting rather than prospective polysomnography data.

Three research directions are worth watching. First, MAESTRO-NASH open-label extension data, expected in 2025 and 2026, will capture longer-term thyroid function and metabolic outcomes that correlate with sleep physiology. Second, investigator-initiated studies pairing Rezdiffra with actigraphy or polysomnography in MASH-OSA overlap patients are beginning to appear in clinical trial registries (ClinicalTrials.gov NCT06312800 as of early 2025). Third, the preclinical literature on hepatic circadian clock restoration via THR-beta agonism, while preliminary, suggests a potential mechanism for sleep-quality improvement that deserves prospective human study.

The American Association for the Study of Liver Diseases (AASLD) 2023 MASH guidance states: "Assessment of comorbid sleep-disordered breathing is recommended in all patients evaluated for pharmacological MASH treatment, given the high prevalence and bidirectional metabolic impact of OSA in this population" [14]. This recommendation predates the resmetirom approval but applies directly to Rezdiffra prescribers.

In the MAESTRO-NASH open-label extension, the 52-week responder data showed that patients who achieved NASH resolution sustained fibrosis benefit at 96 weeks, with no new thyroid or neurological adverse events identified [5]. The extended follow-up period provides at least preliminary reassurance that latent sleep-disrupting effects do not emerge with longer exposure.